TrialPath
Recruiting

Study of ALTO-300 in MDD

NCT05922878 · Alto Neuroscience
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
About this study
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Eligibility criteria
Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
Study design
Enrollment target: 325 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2023-06-08
Estimated completion: 2026-12
Last updated: 2026-10-26
Interventions
Drug: ALTO-300Drug: Placebo
Primary outcomes
  • • To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS). (Change over time for up to week 6)
Sponsor
Alto Neuroscience · industry
Contacts & investigators
ContactAlto Neuroscience · contact · clinical@altoneuroscience.com · 650-200-0412
InvestigatorAdam Savitz, MD, PhD · study_director, Alto Neuroscience
All locations (75)
Site 200Recruiting
Phoenix, Arizona, United States
Site 189Withdrawn
Phoenix, Arizona, United States
Site 187Active Not Recruiting
Yuma, Arizona, United States
Site 193Recruiting
Rogers, Arkansas, United States
Site 218Recruiting
Bellflower, California, United States
Site 318Active Not Recruiting
Carlsbad, California, United States
Site 217Active Not Recruiting
Glendale, California, United States
Site 335Recruiting
Lafayette, California, United States
Site 335Recruiting
Lafayette, California, United States
Site 209Active Not Recruiting
Los Angeles, California, United States
Site 219Recruiting
Mather, California, United States
Site 194Terminated
Mission Viejo, California, United States
Site 267Recruiting
Moorpark, California, United States
Site 197Recruiting
Temecula, California, United States
Site 203Active Not Recruiting
Colorado Springs, Colorado, United States
Site 343Recruiting
Denver, Colorado, United States
Site 345Active Not Recruiting
Evergreen, Colorado, United States
Site 349Active Not Recruiting
Evergreen, Colorado, United States
Site 214Withdrawn
Norwalk, Connecticut, United States
Site 159Terminated
Clermont, Florida, United States
Site 225Active Not Recruiting
Miami Gardens, Florida, United States
Site 190Active Not Recruiting
Miami Lakes, Florida, United States
Site 161Active Not Recruiting
Okeechobee, Florida, United States
Site 221Recruiting
Tampa, Florida, United States
Site 220Active Not Recruiting
West Palm Beach, Florida, United States
Site 238Recruiting
Fayetteville, Georgia, United States
Site 224Active Not Recruiting
Savannah, Georgia, United States
Site 208Terminated
Snellville, Georgia, United States
Site 293Not Yet Recruiting
Stone Mountain, Georgia, United States
Site 317Withdrawn
Blackfoot, Idaho, United States
Site 119Active Not Recruiting
Boise, Idaho, United States
Site 236Recruiting
Boise, Idaho, United States
Site 310Active Not Recruiting
Chicago, Illinois, United States
Site 314Active Not Recruiting
Wichita, Kansas, United States
Site 201Terminated
Marrero, Louisiana, United States
Site 198Terminated
Monroe, Louisiana, United States
Site 288Recruiting
Worcester, Massachusetts, United States
Site 240Recruiting
Mankato, Minnesota, United States
Site 265Recruiting
Minneapolis, Minnesota, United States
Site 279Withdrawn
Hattiesburg, Mississippi, United States
Site 215Active Not Recruiting
Jackson, Mississippi, United States
Site 229Withdrawn
Creve Couer, Missouri, United States
Site 264Recruiting
St Louis, Missouri, United States
Site 231Active Not Recruiting
Omaha, Nebraska, United States
Site 344Recruiting
Las Vegas, Nevada, United States
Site 114Recruiting
Albuquerque, New Mexico, United States
Site 283Recruiting
New York, New York, United States
Site 319Active Not Recruiting
New York, New York, United States
Site 191Terminated
Rochester, New York, United States
Site 192Terminated
Staten Island, New York, United States
Site 199Active Not Recruiting
Hickory, North Carolina, United States
Site 287Recruiting
Rose Hill, North Carolina, United States
Site 268Recruiting
Winston-Salem, North Carolina, United States
Site 202Recruiting
Cincinnati, Ohio, United States
Site 195Terminated
Oklahoma City, Oklahoma, United States
Site 303Withdrawn
Oklahoma City, Oklahoma, United States
Site 216Terminated
Allentown, Pennsylvania, United States
Site 350Withdrawn
Media, Pennsylvania, United States
Site 352Active Not Recruiting
Moosic, Pennsylvania, United States
Site 316Recruiting
Austin, Texas, United States
Site 239Recruiting
Conroe, Texas, United States
Site 102Active Not Recruiting
Dallas, Texas, United States
Site 347Terminated
Fort Worth, Texas, United States
Site 148Withdrawn
Fort Worth, Texas, United States
Site 275Recruiting
Houston, Texas, United States
Site 320Recruiting
Houston, Texas, United States
Site 206Withdrawn
Missouri City, Texas, United States
Site 353Recruiting
Plano, Texas, United States
Site 196Terminated
Richmond, Texas, United States
Site 234Recruiting
San Marcos, Texas, United States
Site 235Recruiting
Stephenville, Texas, United States
Site 207Active Not Recruiting
Clinton, Utah, United States
Site 315Active Not Recruiting
Provo, Utah, United States
Site 277Recruiting
Fairfax, Virginia, United States
Site 211Active Not Recruiting
Roanoke, Virginia, United States
Study of ALTO-300 in MDD · TrialPath